Detailed explanation of the efficacy and side effects of sparsentan/sparsentan

Sparsentan is an innovative drug developed by Travere Therapeutics and is a dual endothelin angiotensin receptor antagonist (DEARA). In recent years, sparsentan has shown promising clinical results in the treatment of immunoglobulin A (IgA) nephropathy and received accelerated approval in February 2023 for reducing proteinuria in adult patients with primary IgA nephropathy who are at risk of rapid disease progression. This approval marks an important breakthrough in the treatment of IgA nephropathy, as it is the first and currently only non-immunosuppressive treatment approved for this disease.

ImmunoglobulinA (IgA) nephropathy, also known as Berger's disease, is a glomerular disease characterized by the deposition of abnormally structured IgA. The deposition of IgA and its related immune complexes in the glomerulus can cause local inflammatory reactions, leading to glomerular damage and dysfunction, which can manifest as symptoms such as hematuria and proteinuria. According to research data, about 30% to 40% of patients with IgA nephropathy may develop renal failure within 20 to 30 years after diagnosis, so early and effective intervention is crucial to improve patient prognosis.

Sparsentan is unique in its dual mechanism of action. It can both antagonize endothelin-1 (ET-1) receptors and inhibit angiotensin II (Ang II) receptors. This dual inhibitory effect helps to reduce the hypertensive state of the kidneys and reduce proteinuria, thus protecting kidney function. Clinical trials have shown that sparsentan can effectively reduce the urine protein/creatinine ratio (UP/C) and has a positive effect on improving the renal prognosis of patients with IgA nephropathy.

Sparsentan's approval was based on interim results from the ongoing Phase III PROTECT trial. This study was designed to evaluate the safety and effectiveness of sparsentane in patients with IgA nephropathy. The recommended dose in the trial is 200 mg once a day initially, which can be increased to 400 mg once a day after 14 days. The specific dosage adjustment needs to be based on the patient's tolerance.

Although the clinical effects of sparsentane are significant, possible side effects still need to be paid attention to during use. The most common side effects include swelling of the limbs, low blood pressure, dizziness, high potassium levels, anemia, kidney damage, and increased levels of liver enzymes in the blood. The occurrence of these side effects is closely related to the effect of the drug on the kidneys and liver, especially when used in combination with a strong CYP3A inhibitor, which requires careful monitoring and dose adjustment.

In addition, sparsentan may present a risk of hepatic and embryo-fetotoxicity, particularly when used during pregnancy. Therefore, the patient's health status must be fully assessed before treatment and the patient must be informed of the possible risks to ensure safe medication use.

Sparsentan, as a new option for the treatment of IgA nephropathy, provides clinicians and patients with a new treatment idea. Its unique dual mechanism of action and relatively good tolerability make it stand out from other traditional treatment options. However, you still need to be vigilant when using this drug and be aware of possible side effects and risks. In clinical practice, a personalized treatment plan should be formulated according to the patient's specific situation, so as to maximize the therapeutic benefits of sparsentane and improve the patient's life.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC10232600/